Biotech Hunter
Biotech Hunter
Home
Companies
Trials
People
Search
Clinical Trials for Therapeutics Inc.
Explore 178 clinical trials worldwide
Search
Showing 1-50 of 178 trials
Active filters:
Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruiting
Sponsor: Therapeutics Inc.
Clinical Trials (178)
NCT06463678
Trial to Evaluate the Efficacy And Safety of IVIEW-1201 In the Treatment of Fungal Keratitis
PHASE2
Not yet recruiting
60 participants
Started: Aug 1, 2026 · Completed: Dec 31, 2027
1 condition
1 sponsor
0 locations
NCT06137638
ENA-001 for Post Operative Respiratory Depression (PORD)
PHASE2
Not yet recruiting
200 participants
Started: Mar 15, 2026 · Completed: Dec 15, 2026
1 condition
1 sponsor
0 locations
NCT07168291
Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma
EARLY_PHASE1
Not yet recruiting
3 participants
Started: Dec 31, 2025 · Completed: Dec 31, 2028
3 conditions
2 sponsors
1 location
NCT07216235
Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical Outcomes
PHASE3
Not yet recruiting
386 participants
Started: Dec 31, 2025 · Completed: Nov 30, 2032
1 condition
1 sponsor
0 locations
NCT07033689
Feasibility Study of Suizenji, in Patients With Unresectable Pancreatic Ductal Adenocarcinoma (SUNRISE-II)
EARLY_PHASE1
Not yet recruiting
10 participants
Started: Dec 1, 2025 · Completed: Mar 1, 2027
1 condition
1 sponsor
1 location
NCT07192432
Gene Therapy for HER-Positive Cancer (SENTRY-HER2)
PHASE1/PHASE2
Recruiting
27 participants
Started: Nov 30, 2025 · Completed: Oct 31, 2033
1 condition
1 sponsor
2 locations
NCT07052760
Imaging of Solid Tumors Using DLL3 SPECT
EARLY_PHASE1
Not yet recruiting
45 participants
Started: Nov 30, 2025 · Completed: Dec 31, 2027
4 conditions
2 sponsors
1 location
NCT07219407
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
PHASE2
Not yet recruiting
30 participants
Started: Nov 3, 2025 · Completed: Feb 3, 2028
6 conditions
1 sponsor
0 locations
NCT07185880
A Phase 1 Study of the Safety and Tolerability of MT-125 in GBM Patients
PHASE1
Not yet recruiting
36 participants
Started: Nov 1, 2025 · Completed: Jun 30, 2027
1 condition
2 sponsors
3 locations
NCT07108153
Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta
PHASE2
Not yet recruiting
16 participants
Started: Oct 31, 2025 · Completed: Jul 31, 2026
1 condition
1 sponsor
13 locations
NCT06921317
GVB-2001 Gene Therapy Via Intracameral Injection for the Treatment of Primary Open Angle Glaucoma
PHASE1/PHASE2
Recruiting
12 participants
Started: Oct 31, 2025 · Completed: Feb 28, 2027
1 condition
2 sponsors
1 location
NCT07219771
A Study to Evaluate the Efficacy and Safey of PTP-001 (MOTYS™) in Knee Osteoarthritis Patients
PHASE3
Recruiting
260 participants
Started: Oct 14, 2025 · Completed: Oct 31, 2027
1 condition
2 sponsors
9 locations
NCT07159763
A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza
PHASE3
Not yet recruiting
5,500 participants
Started: Sep 30, 2025 · Completed: Jan 31, 2027
1 condition
1 sponsor
15 locations
NCT06896188
9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)
PHASE1
Recruiting
12 participants
Started: Sep 22, 2025 · Completed: Dec 31, 2028
1 condition
3 sponsors
1 location
NCT07023835
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
PHASE2
Recruiting
240 participants
Started: Sep 17, 2025 · Completed: Oct 31, 2028
1 condition
1 sponsor
15 locations
NCT07041099
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
PHASE1
Recruiting
36 participants
Started: Sep 15, 2025 · Completed: Mar 15, 2029
3 conditions
1 sponsor
1 location
NCT07161011
Phase 2b Controlled Study of Dosing Techniques - Part B
PHASE2
Active, not recruiting
30 participants
Started: Sep 8, 2025 · Completed: Dec 31, 2025
1 condition
1 sponsor
1 location
NCT07160790
Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 in Patients With Non-erosive Gastroesophageal Reflux Disease
PHASE3
Not yet recruiting
321 participants
Started: Sep 2, 2025 · Completed: Jun 30, 2026
1 condition
1 sponsor
0 locations
NCT06885424
A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products
N/A
Enrolling by invitation
400 participants
Started: Aug 31, 2025 · Completed: Mar 31, 2040
15 conditions
1 sponsor
2 locations
NCT06825559
Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease
PHASE1
Not yet recruiting
6 participants
Started: Aug 31, 2025 · Completed: Aug 31, 2025
1 condition
1 sponsor
1 location
NCT07140380
Phase 2b Controlled Study
PHASE2
Active, not recruiting
30 participants
Started: Aug 20, 2025 · Completed: Dec 31, 2025
1 condition
1 sponsor
1 location
NCT06216366
Rhu-pGSN to Mitigate Proinflammatory Responses to Decompression in Healthy SCUBA Divers
PHASE2
Active, not recruiting
36 participants
Started: Aug 15, 2025 · Completed: Dec 30, 2025
1 condition
1 sponsor
1 location
NCT07086755
Vadadustat for the Treatment of Nonintubated Acute Respiratory Distress Syndrome Due to Pathogen-Associated Lung Injury
PHASE2/PHASE3
Not yet recruiting
1,100 participants
Started: Aug 1, 2025 · Completed: Jul 1, 2026
2 conditions
2 sponsors
1 location
NCT06866795
Phase 1 Clinical Study of GT-220F in Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC)
PHASE1
Not yet recruiting
42 participants
Started: Jul 31, 2025 · Completed: Dec 31, 2025
1 condition
1 sponsor
0 locations
NCT06922890
First-in-Human Clinical Trial of STUP-001, an In Vivo Direct Cell Conversion Gene Therapy for AIS-A/B Chronic Spinal Cord Injury
PHASE1/PHASE2
Recruiting
9 participants
Started: Jul 30, 2025 · Completed: Dec 31, 2027
2 conditions
2 sponsors
1 location
NCT07046494
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder
PHASE2
Recruiting
224 participants
Started: Jul 25, 2025 · Completed: Dec 31, 2026
1 condition
1 sponsor
22 locations
NCT07035990
Safety, Tolerability, and Pharmacokinetics of Multiple Dose Combinations of SION-451 and Complementary Modulators SION-2222 and SION-109 in Healthy Participants.
PHASE1
Recruiting
144 participants
Started: Jul 23, 2025 · Completed: Jun 30, 2026
1 condition
1 sponsor
2 locations
NCT06982352
Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis
PHASE1
Active, not recruiting
48 participants
Started: Jun 15, 2025 · Completed: Apr 15, 2026
2 conditions
1 sponsor
1 location
NCT06552169
REgulatory T Cell Therapy to Achieve Immunosuppression REduction
PHASE2
Recruiting
34 participants
Started: Jun 13, 2025 · Completed: Jun 30, 2031
1 condition
3 sponsors
4 locations
NCT06533579
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
PHASE1/PHASE2
Recruiting
32 participants
Started: May 30, 2025 · Completed: Sep 30, 2031
13 conditions
1 sponsor
8 locations
NCT06682793
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
PHASE1/PHASE2
Recruiting
240 participants
Started: May 22, 2025 · Completed: Mar 31, 2030
17 conditions
1 sponsor
10 locations
NCT06994143
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis
PHASE1
Recruiting
37 participants
Started: May 19, 2025 · Completed: Dec 30, 2028
1 condition
1 sponsor
2 locations
NCT06967259
ENA-001 for Opioid Induced Respiratory Depression
PHASE1
Recruiting
18 participants
Started: May 14, 2025 · Completed: Nov 5, 2025
1 condition
2 sponsors
1 location
NCT06969170
Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder
PHASE2
Recruiting
50 participants
Started: May 6, 2025 · Completed: Aug 30, 2026
1 condition
3 sponsors
1 location
NCT06934382
Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
PHASE1
Recruiting
33 participants
Started: Apr 29, 2025 · Completed: May 30, 2031
1 condition
2 sponsors
1 location
NCT06875310
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
PHASE3
Recruiting
630 participants
Started: Apr 24, 2025 · Completed: Apr 30, 2032
1 condition
1 sponsor
329 locations
NCT06737354
Safety and Efficacy Study of IVB103 Injection in Subjects With Neovascular (Wet) Agerelated Macular Degeneration (nAMD).
PHASE1
Enrolling by invitation
18 participants
Started: Apr 22, 2025 · Completed: Dec 31, 2031
1 condition
2 sponsors
1 location
NCT06708299
CardiolRx in Recurrent Pericarditis Following IL-1 Blocker Cessation
PHASE3
Recruiting
110 participants
Started: Apr 7, 2025 · Completed: Oct 21, 2026
1 condition
1 sponsor
26 locations
NCT06889701
A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants
PHASE1/PHASE2
Recruiting
33 participants
Started: Apr 3, 2025 · Completed: Aug 31, 2026
1 condition
2 sponsors
1 location
NCT05659953
LMT503 First-in-human SAD, MAD, and FE Study
PHASE1
Not yet recruiting
72 participants
Started: Apr 1, 2025 · Completed: Mar 1, 2026
3 conditions
1 sponsor
1 location
NCT06756035
CT-95 in Advanced Cancers Associated With Mesothelin Expression
PHASE1
Recruiting
70 participants
Started: Mar 31, 2025 · Completed: Dec 31, 2028
11 conditions
1 sponsor
8 locations
NCT06911333
AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors
PHASE1/PHASE2
Recruiting
36 participants
Started: Mar 11, 2025 · Completed: Feb 20, 2030
7 conditions
1 sponsor
3 locations
NCT06736418
Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy
PHASE1
Recruiting
65 participants
Started: Mar 10, 2025 · Completed: Jan 31, 2027
2 conditions
1 sponsor
5 locations
NCT06848231
A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy
PHASE2
Recruiting
75 participants
Started: Mar 3, 2025 · Completed: Dec 31, 2026
1 condition
1 sponsor
9 locations
NCT06785454
A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension
PHASE2
Active, not recruiting
48 participants
Started: Feb 28, 2025 · Completed: Jan 31, 2026
2 conditions
1 sponsor
27 locations
NCT06848348
Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain
PHASE2
Recruiting
200 participants
Started: Feb 21, 2025 · Completed: Aug 31, 2026
1 condition
1 sponsor
19 locations
NCT06616025
This Study Will Evaluate the Effectiveness of NTX-001, a Surgical Nerve Repair Product When Used in People With Upper Extremity Nerve Lacerations.
PHASE3
Recruiting
98 participants
Started: Feb 10, 2025 · Completed: Apr 30, 2027
2 conditions
1 sponsor
6 locations
NCT06805474
A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT
N/A
Recruiting
30 participants
Started: Jan 28, 2025 · Completed: May 27, 2025
3 conditions
1 sponsor
1 location
NCT06613360
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
PHASE1
Recruiting
24 participants
Started: Jan 21, 2025 · Completed: Dec 31, 2027
2 conditions
1 sponsor
12 locations
NCT06365840
A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor
PHASE2
Recruiting
30 participants
Started: Jan 13, 2025 · Completed: Aug 31, 2029
2 conditions
1 sponsor
1 location
«
Previous
1
2
3
4
Next